Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALTTO adjuvant lapatinib and/or trastuzumab optimization trial
jRCT2080220464Phase 3Completed
- Sponsor
- Novartis
- Start
- Nov 2007
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
01
Overview
Phase 3, randomised trial of lapatinib and trastuzumab in breast cancer (3 arms), sponsored by Novartis. Started Nov 2007; status: completed.
02
Drugs
lapatinibtrastuzumab
03
Conditions
breast cancer
Beyond the preview
Go deeper on jRCT2080220464.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080220464.